Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06655077 · ClinicalTrials.gov registry record · NA
Incorporating PRO Data Into RA Clinical Encounters Using Health IT
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 554
- Enrollment target
NCT06655077: Completed NA study, sponsored by University of California, San Francisco.
NCT06655077 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 554 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06655077, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 554 participants
- Enrollment target
Study Summary
The goal of this pragmatic clinical trial is to learn if a new health IT tool that was rolled out at UCSF Health rheumatology clinics (the RA PRO dashboard) can help improve the lives of individuals with rheumatoid arthritis. The RA PRO dashboard displays important outcomes for individuals with rheumatoid arthritis, including disease activity, physical functioning, and pain scores in an easy-to-read, digital interface that can be displayed on the computer screen during a clinical visit. These outcomes are tracked over time, so patients and clinicians can see changes across multiple time points. Additional features of the dashboard include displaying medication use over time and recent lab test results. The main questions the study aims to answer are: Does displaying the dashboard during a clinical visit ... 1. reduce decisional conflict when making a medication choice? 2. improve self-efficacy in symptom management? 3. change beliefs about medications? 4. improve medication adherence? 5. improve RA outcomes such as disease activity or physical functioning? Researchers will compare these outcomes in the patients of clinicians who have access to the RA PRO dashboard to those who do not to see if these outcomes change over time. Clinicians with access to the dashboard may choose to share it from the computer screen with patients during the clinic visit. Participants will be asked to complete surveys as part of their routine clinic visits.
Primary Outcome
The SURE Test (Sure of myself; Understand information; Risk-benefit ratio; Encouragement) is a 4-item scale that measures decisional conflict in patients using a binary scale (where 0 = "no"; 1 = "yes") for a simple sum of up to 4 points. A higher score indicates greater decisional clarity.
Interventions
- OTHER RA PRO Dashboard
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 554 participants |
| Start Date | 2020-02-26 |
| Est. Completion | 2023-08-21 |
| Phase | NA |
What the finished NCT06655077 record still lists
NCT06655077 is an interventional study that assigns participants to a tested intervention. The registered 554 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 1 intervention - of which RA PRO Dashboard is the first listed.
NCT06655077 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06655077 about?
NCT06655077 is a clinical study titled "Incorporating PRO Data Into RA Clinical Encounters Using Health IT". The goal of this pragmatic clinical trial is to learn if a new health IT tool that was rolled out at UCSF Health rheumatology clinics (the RA PRO dashboard) can help improve the lives of individuals with rheumatoid arthritis. The RA PRO dashboard displays important outcomes for individuals with rheu...
What is the current status of trial NCT06655077?
This trial is currently completed. It is a NA study. The enrollment target is 554 participants. The study started on 2020-02-26. Estimated completion is 2023-08-21.
What interventions are being tested in trial NCT06655077?
The interventions under investigation include: RA PRO Dashboard (OTHER).
Who is sponsoring clinical trial NCT06655077?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06655077's enrollment target sits among peer trials
554 184th of 2000 higher than 1,817 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
- NCT06840392 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI